Vicuron (NASDAQ:MICU)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Vicuron Charts. Click Here for more Vicuron Charts.](/p.php?pid=staticchart&s=N%5EMICU&p=8&t=15)
Vicuron Pharmaceuticals Appoints Cheryl A. Wenzinger to Board of
Directors
Retired Deloitte & Touche Partner Will Also Oversee Audit Committee
KING OF PRUSSIA, Pa., Sept. 17 /PRNewswire-FirstCall/ -- Vicuron
Pharmaceuticals Inc. (Nasdaq: MICU; Nuovo Mercato) today announced that the
Company has appointed Cheryl A. Wenzinger to serve on its Board of Directors.
Ms. Wenzinger, a retired audit partner with Deloitte & Touche LLP, will also
oversee Vicuron's audit committee.
"Cheryl brings a rare and extremely valuable combination of over 30 years of
general financial accounting experience, focused audit committee expertise and
a solid overall business background," said George F. Horner, III, President and
CEO of Vicuron. "We are very pleased she has agreed to join our board."
While a partner at Deloitte & Touche from 1984 to 2000, Ms. Wenzinger served as
the lead client service partner for numerous private and public companies
predominantly focused on health care, insurance and real estate. She has
significant SEC experience with equity and debt offerings and regulatory
reporting. She currently serves on the Board of Trustees for Delta Dental Plan
of Colorado, where she chairs the audit committee and serves on the strategy
and business ethics and corporate compliance committees. She also was recently
appointed to the Deloitte & Touche Retired Partners Committee. A member of
the Board of Directors of Diversa Corporation since February of 2004, Ms.
Wenzinger also serves as the financial expert on its audit committee.
From 1990 to 2000, Ms. Wenzinger was president of the 8,300-member Colorado
Society of CPAs. In this role, she formed and chaired the "Blueprint
Committee" to align its governance and structure. She served as a member of
the Council of the American Institute of CPAs from 1998 through 2002. She has
also been active in the Denver community, serving on numerous not-for-profit
boards over the years.
Ms. Wenzinger received her bachelor's degree from the University of Northern
Colorado in 1972 and was named the University's Business Alumni of the Year in
2000.
About Vicuron
Vicuron Pharmaceuticals is a biopharmaceutical company focused on discovering,
developing, manufacturing and commercializing vital medicine for seriously ill
patients. In May 2004, Vicuron received an approvable letter from the FDA for
its lead product anidulafungin for the treatment of esophageal candidiasis.
The company's other lead product, dalbavancin, a novel intravenous antibiotic
for the treatment of serious Gram-positive infections, has also completed Phase
III clinical trials. The company's versatile research engine integrates
industry-leading expertise in functional genomics, natural products discovery,
mechanism-based drug design and combinatorial and medicinal chemistry. These
approaches are yielding promising novel and next-generation compounds, many of
which are in the later stages of preclinical development. In addition, the
company has research and development collaborations with leading pharmaceutical
companies, such as Pfizer and Novartis.
Forward-Looking Statements
This news release contains forward-looking statements that predict or describe
future events or trends. The matters described in these forward-looking
statements are subject to known and unknown risks, uncertainties and other
unpredictable factors, many of which are beyond Vicuron's control. Vicuron
faces many risks that could cause its actual performance to differ materially
from the results predicted by its forward-looking statements, including the
possibilities that clinical trials and the results thereof might be delayed,
that the timing of the filing of any new drug application might be delayed,
that subsequent clinical trials might indicate that a product candidate is
unsafe or ineffective, that any filed new drug application may not be approved
by the FDA, that ongoing proprietary and collaborative research might not occur
or yield useful results, that a third party may not be willing to license our
product candidates on terms acceptable to us or at all, that competitors might
develop superior substitutes for their products or market them more
effectively, that a sales force may not be developed as contemplated and that
one or more of its product candidates may not be commercialized successfully.
The reports that Vicuron files with the U.S. Securities and Exchange Commission
contain a fuller description of these and many other risks to which Vicuron is
subject. Because of those risks, Vicuron's actual results, performance or
achievements may differ materially from the results, performance or
achievements contemplated by its forward-looking statement. The information set
forth in this news release represents management's current expectations and
intentions. Vicuron assumes no responsibility to issue updates to the
forward-looking matters discussed in this news release.
DATASOURCE: Vicuron Pharmaceuticals, Inc.
CONTACT: Dov A. Goldstein, M.D. of Vicuron Pharmaceuticals Inc.,
+1-610-205-2312, or ; or Hala Bashir of WeissComm
Partners, +1-212-204-2080, or , or Aline Schimmel of
Burns McClellan Inc., +1-212-213-0006, or , both for
Vicuron Pharmaceuticals Inc.
Web site: http://www.vicuron.com/